Akeso (HKG:9926) swung to an attributable loss of 514.5 million yuan in 2024 from a profit of 2.03 billion yuan in 2023, according to a Sunday filing with the Hong Kong bourse.
The biopharmaceuticals producer swung to a loss per share of 0.60 yuan from earnings per share of 2.42 yuan in the previous year.
Revenue declined 53% to 2.12 billion yuan from 4.53 billion yuan a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。